Genoway - Public Comps and Valuation Multiples

Genoway Overview

About Genoway

Genoway SA specializes in genetic designs to serve genetically modified (GM) mice, rat and cell lines for the biopharmaceutical industries and research industries.

Founded

1999

HQ

Employees

105

Website

genoway.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $25.9M

LTM EBITDA $3.8M

EV

$30.7M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Genoway Financials

As of August 2025, Genoway reported last 12-month revenue of $25.9M and EBITDA of $3.8M.

In the same period, Genoway achieved $1.0M in LTM net income.

See Genoway valuation multiples based on analyst estimates

Genoway P&L

In the most recent fiscal year, Genoway reported revenue of $25.9M and EBITDA of $6.3M.

Genoway expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Genoway valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$25.9M	XXX	$25.9M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$12.5M	XXX	XXX	XXX
Gross Margin	n/a	XXX	48%	XXX	XXX	XXX
EBITDA	$3.8M	XXX	$6.3M	XXX	XXX	XXX
EBITDA Margin	15%	XXX	24%	XXX	XXX	XXX
EBIT	$0.7M	XXX	$1.6M	XXX	XXX	XXX
EBIT Margin	3%	XXX	6%	XXX	XXX	XXX
Net Profit	$1.0M	XXX	$2.1M	XXX	XXX	XXX
Net Margin	4%	XXX	8%	XXX	XXX	XXX
Net Debt	XXX	XXX	$0.7M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Genoway including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $25.9M. EBITDA for the last twelve months was $3.8M. In the most recent fiscal year, Genoway achieved $25.9M in revenue and $6.3M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$25.9M	Analyst estimates available to subscribers	$25.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$12.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	48.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$3.8M	Analyst estimates available to subscribers	$6.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	14.8% EBITDA margin	Analyst estimates available to subscribers	24.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$0.7M	Analyst estimates available to subscribers	$1.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	2.5% EBIT margin	Analyst estimates available to subscribers	6.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$1.0M	Analyst estimates available to subscribers	$2.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	4.0% net profit margin	Analyst estimates available to subscribers	8.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$0.7M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Genoway

This financial data table provides comprehensive performance metrics for Genoway, a company based in France. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Genoway generated $25.9M in revenue over the last twelve months.
The company achieved $3.8M in EBITDA over the last twelve months.
Net income over the last twelve months reached $1.0M.

Fiscal Year Performance

In the most recent fiscal year, Genoway reported $25.9M in total revenue.
Fiscal year EBITDA was $6.3M.
The company maintained a gross profit margin of 48.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 24.4%.
Net profit margin reached 8.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Genoway. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Genoway Stock Performance

Genoway has current market cap of EUR 25.5M (or $29.9M), and EV of EUR 26.2M (or $30.7M).

Market Cap Evolution

Genoway Stock Data

As of September 12, 2025, Genoway's stock price is EUR 3 (or $3).

See Genoway trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$30.7M	$29.9M	XXX	XXX	XXX	XXX	$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Genoway Valuation Multiples

Genoway's trades at 1.2x EV/Revenue multiple, and 4.9x EV/EBITDA.

See valuation multiples for Genoway and 15K+ public comps

Genoway Financial Valuation Multiples

As of September 12, 2025, Genoway has market cap of $29.9M and EV of $30.7M.

Equity research analysts estimate Genoway's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Genoway has a P/E ratio of 28.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$29.9M	XXX	$29.9M	XXX	XXX	XXX
EV (current)	$30.7M	XXX	$30.7M	XXX	XXX	XXX
EV/Revenue	1.2x	XXX	1.2x	XXX	XXX	XXX
EV/EBITDA	8.0x	XXX	4.9x	XXX	XXX	XXX
EV/EBIT	47.1x	XXX	18.7x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	28.9x	XXX	14.0x	XXX	XXX	XXX
EV/FCF	-7.1x	XXX	8.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Genoway Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Genoway Margins & Growth Rates

Genoway's last 12 month revenue growth is 11%

Genoway's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Genoway's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Genoway's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Genoway and other 15K+ public comps

Genoway Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	11%	XXX	8%	XXX	XXX	XXX
EBITDA Margin	15%	XXX	24%	XXX	XXX	XXX
EBITDA Growth	5%	XXX	-31%	XXX	XXX	XXX
Rule of 40	43%	XXX	35%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	42%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	42%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial